BiCNU
Active substance: Carmustine
Manufacturer: Bristol-Myers Squibb
Extract from the prescribing information:
"BiCNU is carcinogenic in rats and mice, producing a marked increase in tumor incidence in doses approximating those employed clinically."
"A frequent and serious toxicity of BiCNU is delayed myelosuppression."
"BiCNU (carmustine for injection) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents."
The above has been extracted from the BiCNU prescribing information on the Bristol-Myers Squibb webpages.